Solar Pharmaceutical Industries (Solar Pharma) on Saturday stated it can purchase 100% of Innovcare Lifesciences in a deal valued at about 2.71 billion rupees ($28.73 million).
The corporate stated the acquisition will assist strengthen its portfolio within the specialty and branded generics phase whereas supporting its long-term progress technique in each home and worldwide markets.
The acquisition, characterised by India’s largest drugmaker as a strategic funding to strengthen its product portfolio, is anticipated to shut on or earlier than July 31, 2026, topic to customary closing circumstances.
Innovcare Lifesciences is engaged within the improvement and advertising and marketing of healthcare and pharmaceutical merchandise, and its addition is anticipated to enrich Solar Pharma’s current choices.
The deal displays Solar Pharma’s ongoing technique of increasing by way of focused acquisitions to reinforce its therapeutic vary and market presence.
